CRIS Current Research Information System

SANTUCCI, MARIA ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.605
AS - Asia 2.893
EU - Europa 2.331
AF - Africa 171
SA - Sud America 123
Continente sconosciuto - Info sul continente non disponibili 107
OC - Oceania 7
Totale 9.237
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.551
VN - Vietnam 846
SG - Singapore 801
CN - Cina 717
GB - Regno Unito 613
DE - Germania 320
SE - Svezia 290
IT - Italia 243
UA - Ucraina 194
HK - Hong Kong 145
FR - Francia 143
RU - Federazione Russa 134
IN - India 120
IE - Irlanda 92
NL - Olanda 86
BR - Brasile 84
JP - Giappone 58
TG - Togo 54
ZA - Sudafrica 54
EE - Estonia 42
FI - Finlandia 37
KR - Corea 33
CH - Svizzera 31
JO - Giordania 27
CA - Canada 25
BD - Bangladesh 22
TH - Thailandia 22
BG - Bulgaria 20
SC - Seychelles 19
BE - Belgio 17
CI - Costa d'Avorio 16
MX - Messico 16
NG - Nigeria 15
AR - Argentina 14
IR - Iran 13
GR - Grecia 12
ID - Indonesia 12
IQ - Iraq 11
PH - Filippine 10
PL - Polonia 10
RO - Romania 9
CZ - Repubblica Ceca 8
SA - Arabia Saudita 8
TW - Taiwan 8
EC - Ecuador 7
LT - Lituania 7
TR - Turchia 7
UZ - Uzbekistan 7
AU - Australia 6
ES - Italia 6
HR - Croazia 6
PK - Pakistan 6
NP - Nepal 5
VE - Venezuela 5
CL - Cile 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
DZ - Algeria 3
JM - Giamaica 3
MA - Marocco 3
CO - Colombia 2
CR - Costa Rica 2
EG - Egitto 2
GE - Georgia 2
IL - Israele 2
KH - Cambogia 2
LB - Libano 2
MD - Moldavia 2
PT - Portogallo 2
PY - Paraguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CU - Cuba 1
ET - Etiopia 1
GI - Gibilterra 1
GM - Gambi 1
GP - Guadalupe 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
MU - Mauritius 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
SV - El Salvador 1
VI - Stati Uniti Isole Vergini 1
ZM - Zambia 1
ZW - Zimbabwe 1
Totale 9.131
Salva come PNG Salva come JPEG
Città #
Singapore 567
Southend 514
Ashburn 380
Chandler 317
Fairfield 315
San Jose 210
Wilmington 173
Seattle 164
Dong Ket 160
Woodbridge 152
Houston 142
Ho Chi Minh City 140
Jacksonville 137
Hong Kong 134
Hanoi 127
Ann Arbor 126
Beijing 114
Princeton 111
Cambridge 107
Dublin 91
Hefei 88
Council Bluffs 82
Santa Clara 74
Boardman 71
Nanjing 60
Lomé 54
Westminster 53
Padova 52
Los Angeles 48
New York 48
Tokyo 47
Lauterbourg 44
Berlin 41
Helsinki 36
Bologna 33
Frankfurt am Main 32
Bern 28
Jinan 28
Buffalo 27
Amman 26
Seoul 26
Shenyang 24
Da Nang 23
Milan 21
Changsha 20
Medford 20
Mülheim 20
San Diego 20
Sofia 20
Falkenstein 19
Falls Church 19
Hebei 19
Saint Petersburg 18
Chicago 17
Abidjan 16
Brussels 16
Abeokuta 15
Haiphong 15
Nanchang 15
Redmond 15
Tianjin 15
Verona 15
Phoenix 14
Guangzhou 13
Taizhou 13
Shanghai 12
Des Moines 11
Hangzhou 11
London 11
Rome 11
Bengaluru 10
Redondo Beach 10
Turin 10
Bangkok 9
Mahé 9
São Paulo 9
Toronto 9
Zhengzhou 9
Dallas 8
Dearborn 8
Jakarta 8
Kuban 8
Montreal 8
Norwalk 8
Washington 8
Xi'an 8
Bühl 7
Jiaxing 7
Johannesburg 7
Munich 7
Ningbo 7
Baghdad 6
Bremen 6
Brooklyn 6
Florence 6
Harbin 6
Long Xuyen 6
Nuremberg 6
Portsmouth 6
The Dalles 6
Totale 5.885
Salva come PNG Salva come JPEG
Nome #
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 278
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 271
9-Hydroxystearic acid upregulates p21WAF1 in HT29 cancer cells. 267
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 248
NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE 236
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 230
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 222
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 220
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 202
Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia 201
14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia 198
9-HSA INDUCES APOPTOSIS AND INCREASES SENSITIVITY TO IMATINIB IN IMATINIB RESISTANT COLON CANCER CELLS 195
Apoptotic death of Bcr-Abl-expressing myeloid progenitors in response to the m-Tor inhibitor RAD001 (Everolimus) is promoted by the nuclear import of c-Abl 192
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor 190
P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors 189
Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia 189
9-HSA INDUCES APOPTOSIS AND INCREASES SENSITIVITY TO IMATINIB IN IMATINIB RESISTANT COLON CANCER CELLS 188
Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase. 187
P53 and beta catenin cross-talk in the medulloblastoma cell line radiosensitivity 184
C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines. 183
HDAC1 (histone deacetylase1) involvement in Chronic Myeloid Leukemia 178
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 177
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 177
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 175
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606 173
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 171
The p210BCR-ABL tyrosine kinase of chronic myeloid leukemia causes resistance to radio-induced apoptotic death by inhibiting the proapoptotic BAX gene 170
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 166
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 166
GENOMIC UNBALANCES ASSOCIATED WITH THE RESISTANCE TO IONIZING RADIATIONS OF A HUMAN OSTEOSARCOMA CELL LINE (SAOS) DETECTED BY COMPARATIVE GENOMIC HYBRIDIZATION (CGH-BASED TECHNIQUE) 161
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. 161
mTOR inhibitor RAD001 (Everloimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-Abl protein 160
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. 160
Modulation of apoptotic signalling by 9-hydroxystearic acid in osteosarcoma cells 157
IPO-trimethylation of histone H3-lysine9 associated with P210 BCR-ABL tyrosine kinase of chronic myeloid leukaemia 156
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 156
The m-TOR inhibitor everolimus complements pro-apoptotic and anti-proliferative effects of imatinib on chronic myeloid leukemia progenitors by promoting the nuclear import of normal c-Abl protein 152
Tyrosine kinase inhibotr STI571 (Imatinib) cooperates with wild type p53 on k562 cell line to enhance its pro-apoptotic effets 152
Genomic instability in the development of non-Hodgkin lymphomas secondary to Hodgkin lymphoma 148
New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells 143
COVALENT MODIFICATIONS OF HISTONE H4 NH2-TERMINAL TAILS ASSOCIATED WITH P210 BCR-ABL TYROSINE KINASE 142
A new class of dual SRC/ABL kinase inhibitors for the treatment of imatinib-resistant chronic myeloid leukemias 141
Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. 141
P210 BCR-ABL TYROSINE KINASE INHIBITS APOPTOTIC CELL DEATH THROUGH MULTIPLE PATHWAYS PREVENTING EARLY MITOCHONDRIAL ACTIVATION 140
Cyclin-dependent kinase 2 (Cdk2) activity at the G1 to S boundary has a role in the resistance of Chronic Myeloid Leukemia (CML) haematopoietic progenitors to the tyrosine kinase inhibitor STI571 (Imatinib) 139
P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2 138
RAD001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia 137
Post-translational modifications of FOXO3a transcription factor associated with the constitutive tyrosine kinase activity of p210 BCR-ABL protein. Implications for new targeted therapies 131
P210 BCR-ABL tyrosine kinase prevents apoptotic cell death through multiple pathways converging at mitochondrial membranes 129
Idetification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. 121
We are very happy and proud of this monographic issue of the Giornale Italiano di Dermatologia e Venereologia. Introduction. 101
La tirosin-cinasi del prodotto p210 di bcr-abl sopprime l'apoptosi mitocondrio dipendente 96
NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE 78
The Haemolymphopathology Italian Group (H.I.G.): an essential resource for the new technical and organization problems troubling modern haemolymphopathology diagnostics 72
Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3 sigma case. 2
Totale 9.237
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.386
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.386
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022928 0 28 86 81 87 58 27 58 31 72 210 190
2022/20231.189 133 205 71 145 82 107 25 51 189 32 85 64
2023/2024304 18 49 16 49 19 79 22 14 8 13 8 9
2024/20251.016 19 149 96 73 181 61 53 62 10 139 15 158
2025/20262.561 217 214 193 164 372 168 214 123 534 211 71 80
2026/2027117 38 79 0 0 0 0 0 0 0 0 0 0
Totale 9.237